Clinipace Worldwide Closes $15M Series C Funding Round
Summary
The round was led by Morgan Stanley Expansion Capital, with participation from existing investors including Hatteras Venture Partners and Brook Private Equity Advisors. The company intends to use the new capital to continue building its therapeutic expertise and global capacity to deliver its services – optimized by TEMPO™, its proprietary eClinical platform, for biopharmaceutical and medical device firms. Led by Chairman and Chief Executive Officer Jeff Williams, Clinipace Worldwide has managed over 500 global contract research and regulatory projects. Its experts bring knowledge and insight into site selection, patient recruitment, clinical operations, data management, medical monitoring, biostatistics, and regulatory affairs to ensure a successful clinical development program through proactive clinical trial management. The company also has offices in Overland Park, Kansas, Boulder, Colorado, Zurich, Switzerland, Munich, Germany, Tel-Aviv, Israel, New Delhi, India, Sao Paulo, Brazil, Buenos Aires, Argentina, and Lima, Peru.